Endogenous serum and lymphatic proteins

Endogenous serum and lymphatic proteins represent a collective group of proteins found within the circulatory and lymphatic systems, with human serum albumin (HSA) being the most prominent member (DrugBank Target DB04891). These proteins are essential for physiological processes such as maintaining plasma oncotic pressure, buffering blood pH, and transporting a wide array of endogenous and exogenous substances, including hormones, fatty acids, and drugs (StatPearls, Albumin). In the context of pharmacology and diagnostic imaging, this group serves as a functional target for blood-pool contrast agents like gadofosveset trisodium (Ablavar). By binding reversibly to these proteins, specifically albumin, these agents achieve a significantly prolonged intravascular half-life and increased magnetic resonance relaxivity, enabling high-resolution angiography (FDA Label, Ablavar). While not a traditional therapeutic target for disease modification, these proteins are critical for the pharmacokinetic behavior of drugs designed for prolonged systemic circulation or targeted vascular imaging (ChEMBL, CHEMBL2364674). Notable safety considerations include the risk of nephrogenic systemic fibrosis in patients with impaired renal function and potential displacement of other protein-bound drugs.

Other names

Serum proteinsPlasma proteinsLymphatic proteinsAlbumin-binding proteinsBlood-pool proteins

Reversible binding to endogenous proteins, primarily serum albumin, which increases the relaxivity and intravascular residence time of contrast agents for enhanced magnetic resonance imaging.